F

ile this under “What were they thinking?”

Novo Nordisk (NVO) has agreed to pay more than $58 million to settle allegations that it failed to adequately alert doctors one of its diabetes drugs may be associated with thyroid cancer, a step that was required by regulators at the time its medicine was approved.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.